Ginsenoside Rg1 protected podocytes from hyperlipidemia-induced damage via targeting the mammalian target of rapamycin (mTOR)/NF-κB/NLRP3 Axis by adopting L-leucine (LEU), the activator of mTOR [98]. The gene discussed is MTOR; the disease is hyperlipidemia.